搜索
ss
ss
关于普米斯
About Us
918曾竣玮

Andy Tsun (Co-founder, VP)

Andy is responsible for Discovery Biology at Biotheus. He obtained his D. Phil. (Ph. D.) from the University of Oxford, and worked as a Postdocotoral Research Scientist/Associate Professor at Institut Pasteur of Shanghai before moving into industry. Andy was previously the Director of Functional Biology at Innovent Biologics, where he was responsible for target selection and lead molecule selection/characterization. During this period, he participated and led the discovery and development of sintilimab until IND filing. Andy also led the discovery and development of multiple therapeutic antibodies to other targets such as OX40, CD47, and LAG-3.
所属分类
Back To List
918曾竣玮
产品描述
[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[产品参数, 参数]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]

Andy is responsible for Discovery Biology at Biotheus. He obtained his D. Phil. (Ph. D.) from the University of Oxford, and worked as a Postdocotoral Research Scientist/Associate Professor at Institut Pasteur of Shanghai before moving into industry. Andy was previously the Director of Functional Biology at Innovent Biologics, where he was responsible for target selection and lead molecule selection/characterization. During this period, he participated and led the discovery and development of sintilimab until IND filing. Andy also led the discovery and development of multiple therapeutic antibodies to other targets such as OX40, CD47, and LAG-3.

关键词:
the
of
as
research
drug
and
project
chinese
new
扫二维码用手机看
未找到相应参数组,请于后台属性模板中添加
There is currently no content to display
Please add data record on website background.

Copyright: © 2021 Biotheus, Inc.     粤ICP备2021122492号      Powered by www.300.cn